NeOnc Schedules FDA End-of-Phase 1 Meeting for NEO212 on November 17

summarizeSummary

NeOnc announced an FDA End-of-Phase 1 Type B meeting for NEO212 on November 17, 2026, to discuss Phase 2 design and a potential accelerated approval pathway, alongside encouraging Phase 1 durability data.

check_boxKey Events · Product Development and Regulatory · NTHI

• FDA End-of-Phase 1 Meeting Scheduled

  In-person Type B meeting with FDA set for November 17, 2026, at White Oak campus to discuss NEO212 Phase 2 design and potential accelerated approval pathway.

• Phase 1 Dose Selected

  Dose escalation completed with 610 mg selected as recommended Phase 2 dose after a dose-limiting toxicity at 810 mg.

• Encouraging Phase 1 Durability Data

  Partial response with ~60% tumor reduction and 21 months disease control in recurrent GBM; ~16 months stable disease in lung cancer brain metastasis patient.

• Regulatory Strategy Discussion

  Company will seek FDA feedback on patient population, endpoints, and whether trial design could support accelerated approval.

auto_awesomeAnalysis · NTHI · Life Sciences

NeOnc has secured an in-person End-of-Phase 1 Type B meeting with the FDA on November 17, 2026, to discuss the registrational path for NEO212. The company will seek feedback on Phase 2 trial design, patient population, endpoints, and a potential accelerated approval pathway. This is a meaningful regulatory milestone for a company with a going-concern warning and only $2.0M in cash as of Q2 2026 — a favorable FDA outcome could materially de-risk the program and improve financing prospects, while an unfavorable one would deepen the cash-runway challenge. The filing also discloses encouraging Phase 1 durability data: a partial response with ~60% tumor reduction and 21 months of disease control in recurrent GBM, and ~16 months of stable disease in a lung cancer brain metastasis patient.